Journal
CANCER CELL
Volume 40, Issue 5, Pages 455-457Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2022.04.007
Keywords
-
Categories
Ask authors/readers for more resources
Androgen receptor negatively modulates CD8(+) T cell-driven antitumor immune response, and targeting the androgen-axis blockade may improve the activity of ICIs in CRPC.
Immune checkpoint inhibitors (ICIs) have limited activity in patients with castration-resistant prostate cancer (CRPC). A Nature article demonstrates that androgen receptor (AR) negatively modulates CD8(+) T cell-driven antitumor immune response and that androgen-axis blockade is a promising therapeutic strategy to improve ICI activity in CRPC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available